A quantum drug development programme has been launched by psychedelic healthcare company PsiloThera.
PsiloThera, a psychedelic healthcare innovation and life sciences company developing psilocybin-based drugs and therapies, has announced the launch of its Quantum Technology Drug Development Programme – a technology that could help solve a number of problems in both drug discovery and drug development.
The company’s focus is on the treatment of indications such as depression, anxiety, post-traumatic stress disorder (PTSD), eating disorders and addictions, as well as cognitive diseases and neurological disorders such as Alzheimer’s disease, dementia and autism.
Innovation in drug development
The company’s specialised treatment programmes will provide care for veterans, first responders and patients with treatment-resistant mental illnesses. The company aims to deploy its quantum technology programme in order to shorten drug development time.
PsiloThera CEO, John Atanasio said: “PsiloThera is among the first companies focused on developing novel therapeutics by deploying quantum technology that can collect and send materials through organic devices. PsiloThera’s strategy is to have its products lead the future of energy-based nutrients and medication delivery systems.
“Quantum technology may lead to advances that could ultimately change the way that humans digest supplements, medications and nutrients. Our Quantum Technology Advisors projects that the technology projects to deliver significant improvements in areas of pharmaceutical dispensing issues and adverse effects.
“Quantum Technology may lead to significant reductions in drug development time and costs, giving PsiloThera a possible major competitive advantage if that were to prove true.”
The Journal of American Medical Association reported in a 2020 study that treatment of psilocybin works better than usual anti-depressant medications. PsiloThera’s vertical business model includes fungi cultivation, Research & Development, drug development, a telehealth platform and PsiloThera Treatment Centres.
